The Polpharma Group is the largest Polish investor in the filed of biotechnology. Being strategic for Poland, biotechnology will provide patients with access to state-of-the-art therapies, and it will give the Polish economy fresh impetus to develop in one of the most innovative sectors.
This policy is in line with the Responsible Development Strategy, while supporting the globalisation of Polish industry, the development of advanced technologies and the accumulation of modern competence in cooperation with the scientific community.
In 2021, the Polpharma Group plans to launch a new biologics production plant in Duchnice near Warsaw, where both biological active substances and finished dosage forms will be manufactured. It will be the largest biotechnology production plant in Central and Eastern Europe which will allow for the company’s global expansion in this most innovative drug group area. With the new plant, the company will be able to render contract manufacturing services to international corporations and build up a cooperation network with other entities.
The project will also open up unique opportunities for employees. The company offers attractive career and promotion prospects in the area of industrial biotechnology, which have been very limited in Poland so far. It also runs the educational programme BioAkademia which is intended to provide practical training to employees to cater for the needs of the new plant in Duchnice, among other things.